IDWeek 2026: olorofim shows promise in second-line invasive aspergillosis

Given the urgent need for an orally administered, safer alternative to AmB, olorofim has strong potential to receive FDA approval for IA in 2027. Overall, the findings of the trial are promising, particularly in relation to renal safety. Given the urgent need for an orally administered, safer alternative to AmB, olorofim has strong potential to receive FDA approval for IA in 2027. Mould-active azole antifungals (MAAs) remain the SOC for the treatment of IA. Credit: Fahroni via Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research,…

Source: Clinical Trials Arena